US, UK Approve Anti-Viral Medication Remdesivir to Treat COVID-19

US, UK Approve Anti-Viral Medication Remdesivir to Treat COVID-19

The U.S. Food & Drug Administration (FDA) recently authorized the use of anti-viral drug remdesivir for emergency treatment for those hospitalized with severe COVID-19. The intravenous drug this week was approved as the first medicine to treat COVID-19 in the United Kingdom.

A treatment might be given an emergency use authorization (EUA) if there are no FDA-approved alternatives to treat a serious or life-threatening medical condition. Developed by biopharmaceutical company Gilead Sciences in the United States, remdesivir is the first treatment to show even a minimal effect on treating COVID-19. Early data suggests remdesivir can shorten recovery time by three days in hospitalized patients.

Remdesivir is not FDA-approved for any medical condition. Remdesivir was originally developed as a possible treatment for Hepatitis C and investigated as a treatment for another deadly viral disease, Ebola.

Global Clinical Trials of Remdesivir to Treat COVID-19

Remdesivir is currently being studied in at least five different clinical trials worldwide. The drug is believed to decrease viral RNA production in COVID-19 disease, thus limiting replication and proliferation of the infection.

syringe-antiviral-injection-remdesivir-approved-for-covid19-treatmentRemdesivir is the first treatment to show even a minimal effect on treating COVID-19. Remdesivir was superior to a placebo in shortening the time to recovery in adults hospitalized with COVID-19, according to a preliminary study sponsored by the National Institute of Allergy and Infectious Disease (NIAID). The study had recruited 1,063 participants at 47 U.S. and 21 international sites.

NIAID ended the trial on remdesivir this month and started giving remdesivir to patients who had been assigned to receive a placebo in the study. The decision, which limits researchers’ ability to collect more data about whether the drug saves lives, was made after 8% of the participants given remdesivir died, compared with 11.6% of the placebo group.

Scientists Work Toward Developing Better COVID-19 Treatments

Thomas J. Lewis, PhD., a research scientist and principal of Good Medicine ChoiceTM, Inc. (GMC), said the pursuit for better treatments for COVID-19 is far from over. GMC practitioners Lewis, Mikhail Artamonov, MD; and Michael Carter, MD; have spent the last three months at the forefront of efforts to fight the coronavirus pandemic. The medical collaborative is currently leading a six-month research study into Cytokine Storms resulting from COVID-19 disease.

“This drug is not a silver bullet, leading to statistically significant improvement in only a very limited subset of infected patients and ‘high mortality’ for those taking it, but it is progress,” Lewis said. “It is safe, and better than any other drugs currently out there for COVID-19, but we must continue to work on developing better treatments.”

Drs. Lewis and Artamonov posited that, as a preventative measure, lowering your cytokine markers, which are measured through blood testing, will be a superior treatment to any drug treatment.

“A broad-based data set from Italy, Korea and China show that healthy people have very low mortality and infrequent severe symptoms from COVID-19. People with poor physical health are going to be vulnerable either from the side effects of the drug or the impact of the disease.

“At the end of the day, the medical field tends to want to be reactive for treatment of disease. It’s our mission to replace the current ‘sick care’ standard-of-care approach with a true ‘health care’ approach,” Lewis said.

In addition to its COVID-19 research, GMC has introduced a variety of doctor-approved supplements and health products that support a healthy immune balance. Visit GoodMedicineChoiceNetwork/Shop/ to order. The company is donating 10% of profits from product sales to Advocates for Disabled Americans, Veterans, Police, Fireman & Families (ADA VETs), an organization working closely with families of disabled veterans and first responders.

NIAID Investigating Remdesivir Plus Anti-Inflammatory Drug Baricitinib

NIAID, part of the National Institutes of Health, is sponsoring an investigational trial of remdesivir plus the anti-inflammatory drug baricitinib. An overactive immune system triggering an inflammatory response causing overproduction of cytokines (cytokine storm response or CSS) is an area of research into the sickest of patients infected with coronavirus. The anti-viral and anti-inflammatory combination is expected to be trialed at approximately 100 U.S. and international sites. Investigators anticipate enrolling more than 1,000 hospitalized coronavirus patients. Find out the top anti-inflammatory foods for immune system balance.

Remdesivir clinical trials found that the drug only significantly helped patients who needed supplemental oxygen. There was no marked benefit for patients who were healthier or those that were sicker, requiring a ventilator or heart-lung bypass machine. The study goes on to warn that “given high mortality despite the use of Remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient.”

Social Share
No comments yet. Be the first one to leave a thought.
Leave a comment

Leave a Comment